VTE RESEARCH
OPPORTUNITIES
Seeking to join, support, develop or share a research project?
Please select one of the following for opportunities which may be of interest.
UK Thrombosis Research Network (UK-TReN)
UK Thrombosis Research Network (UK-TReN) is an informal, clinician led network of healthcare professionals with an interest in thrombosis research.
Aims
- To create a multi-disciplinary network of individuals interested in or actively pursuing thrombosis research.
- To increase the number of CRN portfolio adopted studies pertaining to thrombosis.
- To increase clinician/scientist collaboration in thrombosis.
- To join INVENT, thereby enhancing international collaboration.
Who can join?
Anyone who is interested in thrombosis research!
All allied health professionals, doctors, midwives, nurses, and scientists are welcome.
What are the benefits of joining?
- Ease of access to research-active multi-disciplinary collaborators nationally
- Cross-fertilisation between basic scientists and clinicians
- Influence the future direction of UK-TReN as it forms
- Future access to INVENT benefits (if application successful) https://www.invent-vte.com/
- access to funding opportunities (Dragons’ Den Competition; Kickstarter Awards, ISTH-INVENT Fellowship Awards) and resources
- Training/networking opportunities for HaemSTAR/other registrar groups
- participate in network collaborations, projects, and educational seminars
- participate in networking events
- Voting on INVENT Council with international key opinion leaders to help foster international collaboration in clinical VTE research (2 Council members/country)
How can I be more involved?
Watch presentations from Prof Simon Noble and Prof Dan Horner, given at the inaugural UK-TReN meeting held on 28th March 2023, and find out how you can become involved and part.
HaemSTAR
HaemSTAR is an independent UK-wide network of registrars in clinical haematology, interested in promoting and performing research in classical haematology. Our focus is on collaborative projects across haemostasis & thrombosis, transfusion, general haematology, and obstetric haematology.
Become involved through participation with UK and international research projects.
PETS Trial
Examining the benefit of graduated compression stockings in the Prevention of vEnous Thromboembolism in low-risk Surgical patients: a multicentre cluster
randomised controlled trial (PETS Trial)
This study aims to evaluate the potential benefit of Graduated Compression Stockings (GCS) in the prevention of Venous Thromboembolism (VTE) in patients undergoing short-stay surgical procedures, assessed as being at low-risk for VTE.
THRomboprophylaxis in Individuals undergoing superficial endoVEnous treatment (THRIVE):
THRomboprophylaxis in Individuals undergoing superficial endoVEnous treatment (THRIVE): is a multi-centre, assessor-blind, randomised controlled trial to establish whether in patients undergoing endovenous varicose vein procedures:
- A single dose of pharmacological thromboprophylaxis decreases the risk of VTE
- An extended course of pharmacological thromboprophylaxis decreases the risk of VTE
- Pharmacological thromboprophylaxis is associated with an increased rate of bleeding events
- Providing pharmacological prophylaxis is cost-effective
- There is a signal to suggest the pharmacological agent used affects the rate of VTE
The GRACE trial
The GRACE trial aims to evaluate the potential benefit of Graduated Compression Stockings (GCS) in addition to extended duration pharmacological thromboprophylaxis (EDPTP) for surgical patients at highest risk of venous thromboembolism (VTE).
Thromboprophylaxis in Lower Limb Immobilisation (TiLLI):
A study comprising two linked randomised controlled trials evaluating the effectiveness and cost effectiveness of different methods of pharmacological prophylaxis for patients with temporary lower limb immobilisation.
Yellow card Biobank scheme
The biobank is a two-year collaborative pilot study between the Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England.
Today, side effects account for 1 in 6 hospital admissions, placing burden on both patients and services.
The aim of the study is to improve understanding of how a patient’s genetics may increase their risk of harm from adverse drug reactions. It is hoped findings will lead to improved public health outcomes.
The pilot study is focussed on two topics:
1. Allopurinol induced severe cutaneous adverse reactions (SCARs) including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
2. Direct oral anticoagulants (DOACs) and severe bleeding
How You Can Help
You can support by:
- Sharing Yellow Card Biobank content through your public mailing lists or other communication channels.
- Interacting with/sharing our social media posts to reach a wider audience.
Our main objective is to raise awareness about the Yellow Card Biobank and encourage patients to complete a Yellow Card report, which is crucial to our recruitment efforts.
For further information, please contact
[email protected]; [email protected]; [email protected]; [email protected]
Due to close mid March (extension request under review)
Opportunities to share your research
Thrombosis UK on-line conferences provide an opportunity to present your work, share insights, and collaborate with peers from around the globe.
Look out for news of our next conference when there will be opportunity to submit abstracts for the Poster Hall exhibition. Successful submissions will be showcased as e-Posters in our virtual Exhibition Hall. Covering a wide array of crucial topics, including Coagulation & Natural Anticoagulants, COVID-related thrombosis issues, and Patient-centred care delivery.
Entry is free of charge and aims to foster meaningful discussions, driving forward the standards of care in thrombosis management.
Join us in this collaborative effort to enhance understanding, innovation, and patient outcomes in the realm of thrombosis.
Research News
Worrying risks in a range of unproven remedies for Long Covid.
